This Is Why with Dr. Busti

Hypothesis testing is a core concept in biostatistics and evidence-based medicine. In this This Is Why lecture, Dr. Busti explains how hypotheses guide clinical research design and how clinicians interpret statistical results in medical literature.

Understanding hypothesis testing helps clinicians determine whether study findings represent true differences or random chance. In this lecture, we break down null and alternative hypotheses, Type I and Type II errors, alpha and beta, statistical power, and one-tailed versus two-tailed analysis.

Using the landmark HOPE Trial, Dr. Busti demonstrates how hypotheses are established a-priori and how proper study design strengthens internal validity and confidence in clinical trial results.

This lecture is part of the This Is Why (TIW) Evidence-Based Medicine series with Dr. Busti, where clinicians learn how to interpret and apply clinical research in practice.

Topics Covered:

- What hypothesis testing means in clinical research
- Null hypothesis vs alternative hypothesis
- Type I error (alpha) and Type II error (beta)
- Statistical power and sample size considerations
- One-tailed vs two-tailed hypothesis testing
- Why hypotheses must be defined a-priori
- Interpreting p-values in clinical trials
- Clinical example: the HOPE Trial

This video is part of the This Is Why Evidence-Based Medicine series. Explore the full playlist to continue learning how clinical research works and how to critically evaluate the medical literature.

For additional learning resources, explore High-Yield Med Reviews. TIW members can find a member coupon in their TIW benefits section.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/hypothesis-testing-clinical-research

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

#Biostatistics #HypothesisTesting #EvidenceBasedMedicine #ClinicalResearch #DrBusti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Clinical research design and the NIH clinical research process are explained for clinicians. In this This Is Why lecture, Dr. Busti introduces the foundations of clinical epidemiology, biostatistics, and clinical literature evaluation while walking through the NIH framework for how clinical research studies are designed and conducted.

Understanding how clinical research is developed—from the original hypothesis to publication—is essential for clinicians who interpret medical literature and apply evidence to patient care. This lecture explains the structure behind clinical trials, research protocols, statistical analysis planning, and the ethical oversight required to conduct high-quality clinical studies.

As part of the This Is Why series, this module focuses on the reasoning behind evidence-based medicine so clinicians can move beyond memorizing study results and instead understand how research actually works and how to evaluate the literature correctly.

Throughout the TIW series, Dr. Busti connects clinical research design, biostatistics, diagnostic testing, and critical literature evaluation to real clinical decision-making.

Topics Covered:
- Clinical epidemiology vs biostatistics vs literature evaluation
- Foundations of evidence-based medicine
- The Five A's of evidence-based medicine
- The EBM triad: evidence, clinician expertise, and patient values
- NIH clinical research process
- Study concept development and hypothesis formation
- Protocol development and study design
- Ethical oversight and institutional review boards
- Study implementation and monitoring
- Statistical analysis and interpretation
- Communicating research results
- Reporting standards, including CONSORT and PRISMA
- Foundations for critical appraisal of clinical studies

This lecture is part of the This Is Why (TIW) evidence-based medicine learning series with Dr. Busti. Each lecture builds on prior concepts to help clinicians develop a deeper understanding of clinical research and medical literature interpretation.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/nih-clinical-research-design-steps-process

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

#ClinicalResearchDesign #Biostatistics #EvidenceBasedMedicine #ClinicalEpidemiology #Dr Busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

CHA₂DS₂-VASc score atrial fibrillation is a critical concept for determining when anticoagulation is recommended. In this episode of This Is Why with Dr. Busti, we break down a board-style clinical question to explain when anticoagulation should NOT be started in atrial fibrillation.

Understanding stroke risk stratification is essential for USMLE, NAPLEX, NP, PA, and medical board exams. This episode walks step-by-step through the reasoning behind anticoagulation decisions using the CHA₂DS₂-VASc scoring system.

Topics Covered
- CHA₂DS₂-VASc score interpretation
- Atrial fibrillation stroke prevention
- When anticoagulation is not recommended
- AF anticoagulant dosing traps for board exams
- Warfarin vs DOAC dosing in AF
- Board exam test-taking strategies for AF management 

The goal = make medical education easy and clinically relevant.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/cha2ds2-vasc-score-atrial-fibrillation-board-question

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#afib #atrialfibrillation #cha2ds2vasc #anticoagulation #drbusti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

What is proctalgia fugax, and why does this term matter in real clinical practice? In this episode of This Is Why, Dr. Busti breaks down the meaning of proctalgia fugax, its etymology, how it has been understood historically, and how healthcare professionals should use the term today. This lesson focuses on concept-based learning, helping clinicians connect the terminology to differential diagnosis, disorders of gut-brain interaction, and the practical question of whether brief anorectal pain fits proctalgia fugax or points to something else. If you want to understand the “why” behind the words we use in medicine, this episode will help you think more clearly about anorectal pain, diagnosis of exclusion, and patient-centered clinical reasoning.

The goal = make medical education easy and clinically relevant.

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#proctalgiafugax #medicalterminology #anorectalpain #clinicalreasoning #drbusti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care. In this lecture from This is Why, Dr. Busti will learn about short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care—and on exams like the NCLEX. In this lecture, you’ll learn exactly how SAMAs work, when to use them, and what safety pearls can help you avoid common clinical pitfalls in COPD.

You’ll learn how to:

• Mechanism of action: muscarinic (M3) blockade → decreased bronchoconstriction
• Key drug: ipratropium (Atrovent)
• Common combinations: ipratropium/albuterol (DuoNeb, Combivent)
• Clinical uses: COPD maintenance/symptom relief, COPD exacerbation support, select asthma situations (often as add-on therapy in acute care)
• Routes & devices: MDI vs nebulized treatments, dosing frequency, and practical inhaler/neb pearls
• Adverse effects & warnings: dry mouth, cough, urinary retention (BPH), blurry vision/precipitating angle-closure symptoms if sprayed into eyes, and other anticholinergic considerations
• High-yield comparisons: SAMA vs LAMA (where tiotropium and other long-acting agents fit)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sama-short-acting-muscarinic-antagonist-ipratropium-bronchodilator

Get more with a free membership at https://www.thisiswhy.health/

• Access free downloads from our videos 
• Access deep dive content from Dr. Busti
• Organize content via playlists & collections
• Join live Q&A
• Receive member newsletters
• Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use.

You’ll learn how to:

• What LAMA / antimuscarinic bronchodilators are and how they work
• Where LAMA inhalers fit in COPD therapy and long-term symptom control
• Key differences and practical pearls for common COPD inhalers
• High-yield side effects, contraindications, and patient counseling points
• How to recognize and avoid common med errors and confusion with inhaler names/classes

Drugs covered:

• Tiotropium (Spiriva)
• Umeclidinium (Incruse Ellipta)
• Aclidinium (Tudorza Pressair)
• Glycopyrrolate (COPD maintenance formulations)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/lama-bronchodilators-copd-tiopotropium-umeclidinium-pharmacology

Get more with a free membership at https://www.thisiswhy.health/

• Access free downloads from our videos 
• Access deep dive content from Dr. Busti
• Organize content via playlists & collections
• Join live Q&A
• Receive member newsletters
• Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will break down SABA (Short-Acting Beta Agonist) bronchodilators, like albuterol, for the acute management of asthma symptoms and COPD flare-ups.

You’ll learn how to:

- What SABAs are and when they’re used (rescue vs controller)

- Beta-2 agonist mechanism of action (bronchodilation and smooth muscle effects)

- How fast albuterol works, typical duration, and why it’s “short-acting”

- Core therapeutic uses in asthma and COPD

- How SABAs fit into treatment plans (including “as needed” use)

- Common adverse effects: tachycardia, tremor, palpitations, and more

- Key patient counseling: inhaler technique and when to seek urgent care

Drugs discussed:

- Albuterol (rescue inhaler; MDI and nebulizer)

- Levalbuterol (alternative SABA)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/saba-short-acting-beta-agonists-albuterol-rescue-inhaler-asthma-copd

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#SABA #albuterol #asthma #COPD #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will explain how Long-Acting Beta Agonists (LABAs) work, where they fit in therapy for the management of asthma and COPD.

You’ll learn how to:

- Mechanism of action: beta-2 receptor activation → bronchodilation (airway smooth muscle relaxation)

- Clinical use: LABAs in COPD maintenance vs asthma (must be combined with ICS)

- Onset/duration differences and practical inhaler considerations

- Adverse effects & warnings: tachycardia, tremor, hypokalemia, paradoxical bronchospasm, and key safety concepts

- Therapeutic combos: ICS/LABA combination inhalers and where they fit (including common guideline concepts)

LABA drugs discussed for SEO/review:

- Salmeterol

- Formoterol

- Vilanterol

- Olodaterol

- Indacaterol

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/laba-long-acting-beta-agonists-asthma-copd-bronchodilators-pharmacology

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#LABA #LongActingBetaAgonist #Asthma #Bronchodilators #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will break down pioglitazone and the thiazolidinediones (TZDs) so you can confidently explain the mechanism, clinical use, side effects, and key contraindications for type 2 diabetes (T2DM).

You’ll learn how to:

- TZDs (pioglitazone): where they fit in type 2 diabetes (T2DM) therapy

- Mechanism of action: PPAR-γ agonist → increased insulin sensitivity (muscle/adipose) and improved glucose utilization

- Expected impact on A1C reduction and how long these drugs take to show benefit

- Practical comparisons: pioglitazone vs rosiglitazone

Side effects & safety (high yield)

- Weight gain and edema / fluid retention

- Heart failure risk (when to avoid TZDs)

- Fracture risk with TZDs

Drugs covered for SEO / review

- Pioglitazone (primary focus)

- Thiazolidinediones / TZDs (drug class)

- Rosiglitazone (comparison)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tzd-thiazolidinediones-pioglitazone-type-2-diabetes-pharmacology-review

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#pioglitazone #thiazolidinediones #tzd #type2diabetes #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Dr. Busti covers one of the most-tested Type 2 diabetes drug classes—sulfonylureas. If you’ve ever mixed up glyburide vs glipizide, worried about hypoglycemia, or wanted a clear “when do I pick this?” framework, this drug class review is for you. In this lecture from This is Why, Dr. Busti will break down Sulfonylureas (Glyburide, Glipizide) step-by-step so you can confidently in the context of treating type 2 diabetes (T2DM).

You’ll learn how to:

- Mechanism of action: how sulfonylureas increase insulin release

- Clinical use: where sulfonylureas still fit in modern Type 2 diabetes management

- Drug comparisons: key differences between glyburide, glipizide, and glimepiride

- Adverse effects: why hypoglycemia risk matters, plus weight gain and common pitfalls

- Safety & patient selection: older adults, renal impairment, missed meals, and other high-risk scenarios

Key drugs covered:

- Glipizide

- Glyburide 

- Glimepiride

- (Plus core concepts of oral hypoglycemics, insulin secretagogues, and antidiabetic drugs)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sulfonylureas-glipizide-glyburide-type-2-diabetes-pharmacology

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#sulfonylureas #type2diabetes #glipizide #glyburide #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.